fig2

Figure 2. The sensitivity to MDM2 antagonists RG7388 in ALL cell lines and childhood ALL primary cells. (A) Wild-type TP53 Nalm6 cell line is significantly more sensitive to growth inhibition by RG7388 treatment compared to mutant TP53 CCRF-CEM cell line; (B) 10 pediatric ALL samples exposed to RG7388 (0.5 μM) for 72 h. RG7388 markedly decreased cell viability in most samples while assessed by MTT assay; (C) dot-plot of % viability for 10 pediatric ALL samples exposed to RG7388 (0.5 μM) for 72 h. Data shown are the average of three independent experiments and error bars represent SEM. ALL: Acute lymphoblastic leukemia.